Molecular Quality Controls Market Size, Trends and Growth Analysis by 2027

The molecular quality controls sector is projected to grow significantly, reaching an estimated US$ 372.64 million by 2028, up from US$ 184.62 million in 2021. This growth trajectory indicates a compound annual growth rate (CAGR) of 10.6% from 2021 to 2028.

The expansion of this market can be primarily attributed to several key factors. Notably, the increase in funding for genomics research, the decreasing costs associated with sequencing technologies, and the rising incidence of genetic disorders are all contributing to this upward trend. However, the market faces challenges, particularly due to a shortage of skilled professionals, which may impede its growth.

Molecular diagnostics techniques are essential for identifying disruptions in specific DNA or RNA sequences. These disruptions can manifest as single nucleotide polymorphisms (SNPs), deletions, rearrangements, or insertions, which are linked to various health conditions, including infectious diseases, cancers, viral infections, and sexually transmitted infections (STIs).

According to the Flu Facts and Statistics report, there were approximately 31.4 million outpatient visits related to influenza during the 2017-2018 season. The report also indicates that between 5% and 20% of the US population contracts the flu annually. Furthermore, data from the National Cancer Institute reveals that in 2020, around 1,806,590 new cancer cases were diagnosed in the United States, with an estimated mortality of 606,520. Projections suggest that the number of cancer patients could reach 19 million by 2024. The high prevalence of infectious diseases and the increasing rates of cancer are driving demand for molecular diagnostics, which provide precise disease identification and facilitate the implementation of precision medicine.

Governments are increasingly prioritizing research and development in precision medicine. For instance, in 2015, the US government initiated the Precision Medicine Initiative (PMI) to enhance awareness and promote advancements in this field. Consequently, the growing emphasis on molecular diagnostics presents significant opportunities for stakeholders in the molecular quality controls market.

The market is categorized by product type into independent controls and instrument-specific controls. In 2021, the independent controls segment held a larger market share. These controls are recognized for their unbiased nature, high precision, and exceptional sensitivity, all of which can be achieved in a short timeframe. The adoption of independent controls is on the rise due to their diverse applications and lower operational costs. Additionally, these controls are produced separately from reagents, calibrators, and instruments, ensuring reliability and enhanced sensitivity. The advantages provided by independent controls, along with the introduction of new products, are anticipated to drive the growth of this segment in the forthcoming years.

Key organizations and resources that inform the analysis of the molecular quality controls market include the World Health Organization (WHO), National Health Service, Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information, National Institutes of Health, and the Personalized Medicine Coalition, in addition to various company websites.